Time Emotional Intelligence for Agentic Avatars, Enabling More Natural AI Interactions Across Marketing, Sales, Training, and Learning – IT Business Net

Kaltura (Nasdaq: KLTR) said it won “Best Event AI Technology” at the Eventex Awards for the fourth straight year. The company attributed the win to its Agentic Avatar event assistants, including real-time conversational features and analytics. Kaltura reported powering 9,000+ events for 1.3 million attendees, with 69% registration-to-attendance and 51% post-event participation.

Ericsson (ERIC) and Verizon (VZ) partnered to deploy AI-driven automation in Verizon's radio access network. Verizon plans a nationwide rollout of Ericsson's Intelligent Controller platform, which has shown throughput gains of up to 8.9% downlink and 8% uplink. Verizon will also develop its own rApps. ERIC shares were down 1.31% at $10.94, while VZ shares were up 0.28% at $45.17.

Kairos Pharma (KAPA) reported positive interim results from a Phase 2 trial of ENV-105 plus apalutamide in metastatic castration-resistant prostate cancer, showing a median progression-free survival of 17.7 months compared to 2 months with apalutamide alone. The trial will now focus on first-line therapy after enzalutamide. ENV-105 targets CD105, a protein linked to treatment resistance. The company is presenting these findings at the Cancer R&D 2026 conference.

Dell Technologies (DELL) shares rose 4.6% after a 17% two-day decline, driven by Super Micro Computer's raised revenue guidance and a new AI security partnership with CrowdStrike and NVIDIA. The broader market showed modest gains, with tech and AI infrastructure stocks recovering. Investors await Dell's fiscal Q3 2027 earnings on November 24.

Samsung's second Texas chip plant, Taylor Fab 2, may be nearly fully utilized by AMD for high-bandwidth memory production, according to Maeil Business Newspaper. The plant, set for 2030, will make logic base dies for AMD, paired with DRAM from Samsung's South Korean fabs. This deal is significant for Samsung's foundry business, competing with TSMC. The plant's 2nm process could also benefit Samsung's Exynos chips for future Galaxy phones.

CERo Therapeutics (CERO) has treated seven patients in its Phase 1 CER-1236 clinical trial for blood cancers, including AML, MDS, and MF. No dose-limiting toxicities were observed in the second cohort. The trial is ongoing, with safety and preliminary efficacy being evaluated. CERo plans to report progress as the study advances.